PTPN18

Across TCGA pan-cancer cohorts, PTPN18 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PTPN18 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PTPN18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTPN18 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where PTPN18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.662	0.897	<.001	24	view →
LSCC	DFS	Median	II,III,IV	0.820	1.000	.002	21	view →
PDAC	DFS	Median	All	0.592	0.344	.008	17	view →
LUAD	DFS	Quartile	II,III,IV	0.892	0.379	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PTPN18–HNSC (DFS)

Open the HNSC breakdown →